loading page

MR pathway in retinal health and diseases
  • Francine Behar-Cohen,
  • Min Zhao
Francine Behar-Cohen
1 Assistance Publique - Hôpitaux de Paris, Hôpital Cochin Ophtalmopole, 75014 Paris, France 2 Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Inserm, From physiopathology of retinal diseases to clinical advances, 75006 Paris, France.

Corresponding Author:[email protected]

Author Profile
Min Zhao
Centre de Recherche des Cordeliers
Author Profile


In the retina, mineralocorticoid receptor (MR), expressed in vessels, glial and neuronal cells, is mainly activated by glucocorticoids. Under pathological conditions, ocular MR expression and corticoids change, leading in most cases to MR overactivation. Experimental models using MR agonists or antagonists, administered systemically or intraocularly, acutely or chronically and transgenic models, allowed to identify the deleterious consequences of MR pathway overactivation. Among them, oxidative stress, inflammation, deregulation of hydro-ionic channels, alteration of choroidal vasculature, angiogenesis and cell death, are common to major retinal diseases. Specific MR antagonists showed efficacy in models of diabetic retinopathy, ischaemia, retinal and choroidal angiogenesis and in models of glaucoma. It is highly likely that MR antagonists will find a place in the therapeutic arsenal of age-related macular degeneration, diabetic retinopathy, glaucoma and in pachychoroid associated diseases. Their use in humans is still limited by the need of biomarkers of MR activation and specific ocular formulations.
26 Aug 2021Submitted to British Journal of Pharmacology
26 Aug 2021Submission Checks Completed
26 Aug 2021Assigned to Editor
31 Aug 2021Reviewer(s) Assigned
12 Oct 2021Review(s) Completed, Editorial Evaluation Pending
18 Oct 2021Editorial Decision: Revise Minor
29 Oct 20211st Revision Received
03 Nov 2021Submission Checks Completed
03 Nov 2021Assigned to Editor
10 Nov 2021Reviewer(s) Assigned
19 Nov 2021Review(s) Completed, Editorial Evaluation Pending
22 Nov 2021Editorial Decision: Accept